Sunday, December 30, 2018 1:25:29 PM
- Eurofins
- Matis
- Exova
- Intertek
The first step in fish oil refining (short path distillation) removes most of the contaminants like mercury. Not all DS makers are created equal. Clearly some are more responsible than others.
Here's a lab posted voluntarily to Ifos for the OmegaVia 500 EPA rTG (which I've described in an earlier post as being a voluntary organization for the more responsible DS makers to submit their labs for a given batch of O-3). I myself would not be worried about 10mg of DHA in a 500 mg pill even if I had CVD. Also, the color is removed in the processing of the fishoils to make it clear as I stated in an earlier post. It's called the Gardner score - for V the Gardner score is 0 after processing (show the purity to the naked eye). Natural fish oils vary depending on what the fish have been eating - their scoring could range from 8-14. If the fish have been eating more krill than the oil will be more red. If they have been eating more copapods or worms then the oil will usually be more yellow.
I think its important to remember that Dr. Preston Mason's video - while I thought it was very good is still a marketing tool to promote V created by a biomedical research firm for AMRN - they crank out studies on demand. That doesn't diminish it's message, but I thought when I watched the video originally posted the week after AHA by Zu as I recall, that it was a little bit wonky regarding the processing slides and that fishoil is used to feed animals (like for aquaculture).
We all are animals. The FDA approval processes to certify plants are practically the same, just parallel, regarding approvals for human or pet food plants for example. The reason? Because some Americans eat pet food.
Lipid oxidation is a problem for all oils - Americans consume a lot more soy and corn oil than fish oils. We should start with reducing our edible oils consumption.
Global oils consumption by type:
I don't know if anyone else on the board has read Dr. Cate Shanahan's book "Deep Nutrition" (first edition was 2008 and then she updated it last year) - I just started reading it. She's a PHd in Biochemistry out of Cornell and a MD from Rutgers. Plus, she spent 10 years in Hawaii studying ethnobotany. Pretty fascinating especially her focus on epigenetics and it more than helps her cover for the lack of nutrition training in a typical MD curriculum as she said. Also, in the hierarchy that is modern medicine nutrition is lower on the hierarchical totem pole compared to other subject areas. Preventative medicine is often seen as a "womans" domain, ...or so I've heard.
Strange since maybe if there had been enough other doctors grounded in the science they could have more effectively challenged Dr. Ancel Keys back in the 50's before we got into this CVD mess. US soy consumption (and I believe edible oils are about 30%? of our 1800-3000 calorie American diet...)
I may read this one next:
Typical medical school curriculum (the 4 years before residency) - I don't see too much human nutrition:
I wonder if Dr. Preston Mason is still planning on presenting in Portland at the end of Feb. at the Clinical Lipid Update I may drive down to see if can listen in.
Recent AMRN News
- Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual • GlobeNewswire Inc. • 11/11/2024 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 08:42:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/30/2024 08:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 08:10:08 PM
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 10/30/2024 08:05:00 PM
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM